Acorda agrees to enter agreement with Scopia that includes bringing two from Scopia capital to the board this week! Don’t forget this is the letter from Scopia last August: We are writing this letter to communicate our desire for management and the Board of Directors (the “Board”) to pursue an immediate review of all strategic alternatives, including a sale of the Company.We admire the business that you have built since founding the Company over 20 years ago. The Company raised $850M in capital to develop Ampyra, add commercial infrastructure and acquire pipeline assets. Unfortunately, today the Company is only valued at $1.2B by the public markets.While we have been supportive of the Company’s strategy to this point, we believe it is now time to sell the Company. Had the Company prevailed in the Ampyra litigation, Acorda would have been a unique company with a path to $1B in revenues and significant standalone value. Unfortunately, the Company was unsuccessful, and it has now crossed the Rubicon. In 2018 the business will revert to burning cash with a levered balance sheet and no clear timeline to return to profitability. These are treacherous waters. At the same time, recent acquisitions of both Cynapsus ($624M) and NeuroDerm ($1.1B) speak to the strategic value of late stage assets in Parkinson’s disease. Acorda is a more valuable acquisition candidate than either of these companies.